Jean-Pierre DedetR MelognoFernando CárdenasL ValdaC. DavidVictoria GallardoM TorrezL. Dimier-DavidPhilippe LyèvreM E Villareal2026-03-222026-03-221995https://pubmed.ncbi.nlm.nih.gov/7614666https://andeanlibrary.org/handle/123456789/49705Citaciones: 26Mucocutaneous leishmaniasis (MCL) is endemic in the tropical Amazonian lowlands of Bolivia, an area that regularly receives influxes of migratory populations. In these new agricultural development areas, a campaign to diagnose and treat the disease was carried out between 1989 and 1992, in order to provide direct access to MCL treatment in the endemic areas at a standard equivalent to that offered in the urban centres in Bolivia. The campaign led to the creation of decentralized local centres for diagnosis and treatment of the disease. A campaign to inform the population about leishmaniasis was also undertaken and courses were run to educate medical and paramedical personnel. As a result of the campaign, 3285 cases of leishmaniasis were diagnosed, including 2152 cutaneous and 326 mucosal forms. Also, a total of 1888 cases were treated, 1677 of which cutaneous and 211, mucosal.enLeishmaniasisEndemic diseaseMedicineEndemic diseasesTropical diseasePopulationCutaneous leishmaniasisMucocutaneous zoneGeographyDiseasearticle